Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$nwbo #dcvax #glioblastoma #gbm @ft @faulkingtruth #CitadelScandal #apes $amc $gme https://t.co/FSm3K8lcOv
— rj (@sharpie510) April 15, 2024
"When you are on the right track, you will face massive resistance from virtually every angle. When you are off track, no one will attack you because you are not a threat to anyone's technology. They will just let you sink yourself".
Things are usually not black and white in the world . For example there are people who when not succeeding to the degree or rate they want will blame everyone else but themselves for it .
The daily 100% BS.
The update for end of March was just posted.
Sorry Donut Dude, but I nodded off half way through your irrational Karen-induced speculative out burst.
Calm down dearest !
You lack integrity. You are merely a grifter—a latecomer to the party, how convenient—who somehow parasites on the many parties that are colluding to make DCVax-L as expensive as possible while delaying its delivery to patients.
Your book will likely be a great addition to the fantasy genre.
Of course, you see no need to clarify. We are well beyond the point of no return, where your postings lack any coherence and your assertions have been thoroughly refuted by those who truly understand what due diligence entails. Your paid narrative clearly states - as it does for the dozens of your colleagues here - that you refute any and all information, that your fud counters, and since that is obviously often impossible, then at least ignore it, or fudge it away under the pretence that "we are all ultimately the same on this board. I am not more wrong, than you are right".
How convenient of you to introduce a ruleset, that undermine the need for due diligence and juxtaposes it with the nonsense you are limited to exhibit.
Your new tactic is to level everything written on this board to the same lowest denominator of nonsensical BS to which you have so generously contributed in your short time here.
You are right. Your integrity is probably not defined by pennies.
We are clearly way into silver coins.
Let me show you an example of due diligence, which exhibits your second account Inquiriq, who continue to sell that MHRA uses business days and not calendar days even though he/she/it/you have been trying to ...
April 8th. 2024
Excellent comment.
Thanks
Wrong. There is a truth in this matter and you are not on the side of truth. You and the dozen other characters here who grossly misinterpret the facts are not world leading oncologist like the 70 who signed off on the JAMA publication for DCVax-L. Their judgment holds more bearing than any BS you could ever whip up.
I say again, If you write a book about GBM it will have NOTHING to do with NWBO or DCVAX or their successful Phase III trial. That’s a fact! Nip off.
Typical answer from you, you must be a politician, saying a lot without actually saying anything meaningful.
I don't know if paying dividend will work, doubt it or they would have done a long time ago.
As this entire Board is almost entirely filled with desperate speculative commentary, based on no more than shareholders’ ‘beliefs’, I see no need to clarify my judgement calls.
We are all, ultimately, eating bits the same shit-sandwich, at the end of the day.
I am no more wrong , than you are right.
So please don’t pretend that you’re in some elevated righteous position over me, just because, you hold some, increasingly worthless shares.
My integrity is not defined by pennies.
This is the webpage from Institute for Immunology at Mainz. This is the core research of the institution. Does the description look familiar? The interesting part is that this webpage was setup on June 10, 2018 according to WayBackMachine and remains unchanged ever since. Don't be surprised if there is another paper. Recall the following paper only dealing with a specific subtype of rectal cancer which accounts for about 3% of rectal cancer. The paper from the collaboration trial if there is one is going to be in limelight.
https://www.mskcc.org/news-releases/asco-2022-100-complete-response-rate-mmrd-locally-advanced-rectal-cancer-seen-pivotal-immunoablative-neoadjuvant-immunotherapy-clinical-trial
Well I, for one, think your post offers a very good take on the current situation.. so thank you! :)
Thanks, starric.
The version of DC vaccine developed by Italian researchers is just for research purpose. They started treating melanoma since 2001 and I am really surprised that they haven't included poly-iclc in their formulation. No way can be compared with what we have.
If the strategy would work they could do it with even less and I'd be fine with it.
I believe the only ones who can build that sort of naked short position is MM's selling shares they don't own, so it would be the MM's holding the naked short and selling shares to customers who have no idea that's what they own. If in fact this is the case, Posner may have a much bigger case than spoofing against the MM's.
If even the tiniest dividend cleans up the naked situation it will cost the MM's dearly.
Gary
Join us Friday, April 19, 2024 for the @UNMC_NeuroSurg 42nd Annual J. Jay Keegan Memorial Lecture as we welcome internationally renowned neurosurgeon, Dr. Linda Liau! Details below! @unmc @UNMCCOM @NebraskaMed @UCLANsgy pic.twitter.com/5ODnyI8XQs
— UNMC Department of Neurosurgery (@UNMC_NeuroSurg) April 15, 2024
Why could they not issue a dividend of .0001?
This site can correct me, but I believe the following would cause all short shares to be filled with actual shares:
1- being bought out.
2- merger with another company.
3- margin call when share price gets to a certain amount.
4- when a dividend is given...
BTW, a $0.01 per share dividend would cost the company +/- $15 million I believe but would be WELL WORTH it to the company in return for the massive increase in share price assuming the amount of naked short shares exist which we have been told...
Thank you Hyperopia. Until now I somehow missed your post and
just read it now. I completely agree with the contents of your post
as to the reasons it took so long to get to this point and I have rarely
faulted NWBO for most of the problems (delays, low SP etc.) since it
has been clear to me for a long time that a number of powerful actors
have been trying to destroy our little company.
While I perfectly understand the importance of the breakthrough
technology of Flaskworks and its superiority over the artisan methodology,
I do not know whether or not at the time of MAA approval, this automated
methodology would have already received the required MHRA approval.
Therefore with regard to whether NWBO starts with the artisan or automated
technology. I am on the fence but I am confident that the company is not on
that fence, has planned all the steps that have to be followed and is ready
for all contingencies.
Gus1212 - I believe $GNS actually pursued that strategy. It did cause the stock to pop. It may have gone to $2, but it's at $.43 at the moment so.
I liked the idea someone had many months ago.
Give out a .01 penny dividend with the first month's revenue after approval.
I think all shares have to be accounted for.
But people here know much more than myself.
Don't Make Me Leak - Alice
Question: Let's assume there are 2 billion naked shares. Could someone explain how those shares remain naked/unaccounted for, and what the mechanics are that would expose them?
Nemesis18,
Thanks for the heads up about the next Phase Five report and its potential coauthors; ) . Best wishes
https://www.researchgate.net/publication/376903848_Insights_into_an_Autologous_Dendritic_Cells_Vaccine_for_Glioblastoma_First_Step_Results_from_a_Phase_II_Study_CombiG-Vax
Preprint I didn’t realize was coming. Ridolfi is also working on Mesovax
https://www.esmoiotech.org/article/S2590-0188(23)00187-9/fulltext
Looking at the links page, isn't an April update a little late?
https://www.gov.uk/government/publications/marketing-authorisations-granted-in-2024#full-publication-update-history
Maybe this Thursday
25 March 2024
Marketing authorisations granted 1 March to 14 March 2024 have been added.
7 March 2024
Added Marketing authorisations granted 15 to 29 February 2024
21 February 2024
Marketing authorizations granted from 1 to 14 February 2024 have been added.
8 February 2024
First published.
Which literally has absolutely NOTHING to do with this company or DCVax-L. You’re just here because we are a captive audience.
Thanks Mike, it seems that the UK really is publishing what happens about 10 days after the period they're reporting on, it covers a two week period, so it could be roughly 25 days after the actual approval. I would think we'd get a new update shortly, but it will not be current, it will be for the last half of March.
I think it's quite certain the company can disclose action from the regulator, and legally must do so withing a short period of time. I believe the FDA allows 4 days, I'm uncertain of UK requirements. Of course as we learned in the Martha Stewart case, anyone caught acting on the information prior to an official announcement could be charged with insider trading.
I would hope that the company has a well planned program for releasing the information once they know, but it could very well differ depending on when they learn of the decision. In a decision made early in a week, I'd hope they issue and act ASAP, on the other hand, if it's Thursday or later that they get an approval, if allowed an announcement before the bell on Monday, or even an announcement on Saturday or Sunday with a webcast to discuss what's happening would be great for a well organized release of the approval.
Let's see what happens with the next UK release, but I wouldn't expect anything before May given the delay in the data that's reported.
Gary
If you write a book about GBM it will have NOTHING to do with NWBO or DCVAX or their successful Phase III trial.
Nemesis18:
Post# 676116 - "isn’t it interesting that you (DCVax-L Trial) should step up to a long term survivor of GBM4 (Speaking of own self), whilst attempting to profit of a vaccine that is alluded to increase the likelihood of that kind of suitability"... Pairs well with Post# 676129 - "I never had the vaccine (DCVax-L)" & Post# 676136 - "I make no claims against The US Company, as I have had zero involvement with them (NWBO)."
Post# 676144 - "UK Regulatory Authorities only make judgment calls after thorough independent investigations, which has little to do with mine or your opinion on the matter."
Post# 676153 - "I only nip in to this forum, to offer a word of caution, to calm down your expectations of riches to come." Nip out why don't you?
The silent witness can't be you Nemesis, since you have
been for some time the most prolific lying loudmouth on
this MB.
You're correct Lykiri; The MHRA timeline is in calendar days. This is well understood, but some people are trying to confuse new investors.
I think we all know that the different regulators do things in different way. In the case of the FDA for higher priority approval, a PDUFA date is established after the acceptance of a BLA or NDA 6 months after its acceptance. In the UK they're trying to do things faster, it was 150 days after the application is filed, now it's been reduced to 120. A pause is built in, where after an initial review, information could have been requested and the pause wouldn't end until that information was provided, people here who seem to know indicated no such request came from the UK regulators. None of us know this to be a certainty, however the company does, if they've been asked for nothing the total decision period should remain 150 days, or even be accelerated to 120 days based on the latest guidance.
I'm not saying that we're guaranteed an approval at 150, or even 120 days will happen, however, if it doesn't it will need to be explained by the regulator to NWBO, and the company will be responsible for telling us. Personally I like our chances, but if further delays result, I have no doubt that the company can deal with it.
The UK has a pretty good history of meeting or beating their approval guidance on products they approve, that stated I believe that it could happen any day, but something almost certainly by May 22nd. By that logic, April 22nd would be the key to a 120 day decision. Forget discussion of the EDEN being involved in the UK decision, they have already approved commercial production manually, so we can get started in the UK and transition when the EDEN is approved to do so.
Gary
I read it and it does not specify 'working days' it just says days. Imo could be calendar days or potentially working days but just says days. Would be a nicer board if people could avoid the insults and name calling. We have enough challenges with nwbo's communication style as it is
I have no idea. :)
Not seeing anything in there about "working" or "business" days... just plain ol' days...which was the subject of the post your responded to.
He has no insight into reality. Just works for the 7 market makers spreading FUD.
Lacks objectivity. LOL
It is therefore disappointing that due to key methodological limitations, the DCVax-L trial ultimately failed to provide sound conclusions about the potential efficacy of such approach for patients with glioblastoma.
https://pubmed.ncbi.nlm.nih.gov/37012085/
Sure did... Ignorance is not bliss
They contend NWBO are timing Eden approval with maa approval. I’m saying, imo, Eden is:
1. “Several” months out from early February having gmp grade authorized machine made, according to NWBO.
2. Several additional months out from getting “validation” of those machines conducted.
3. Additional weeks to months from getting engineering runs conducted and that data turned into MHRA.
3. Additional weeks to Months from getting a determination from the MHRA.
In no way does that fit a 150 day timeline from the beginning of this year for maa approval. Senti, who often bemoans NWBO time scales, should know better.
If what hyperopia and senti say is true, then it would mean delay of the maa timeline, not the other way around.
I do believe NWBO is trying to get Eden approved, but to relate it to maa timing is a senti hyperopia creation, not a NWBO announcement.
What good does speculating do? Raise hopes that approval will be a bigger event than just approval? Yeah, that’s exactly what it does.
They should know better.
Barely holding 50 cents
Won't be long now!
Can someone please post Dr. Keyoumars Ashkan Secretary contact.
Thanks in advance.
Always seems like I know some one that can use this treatment.
But I find it hard to approach this person and provide the details.
iclight,
Calling Drs Linda Liau and Keyoumars Ashkan shady and their work a scam is a pretty bold statement that is clearly countered by the peer review of Phase 3 L trial results in JAMA Oncology. This coming from an anonymous poster who can find no good in what these doctors have done for their patients with Dr Linda Liau’s vaccine and NWBO’s ability to move it into a commercial scale production model. Hmmm.. something’s wrong with this picture, maybe you stepping to the side lines for the next pic will clear things up ; ). Best wishes.
Neither one of the posts you quoted say that they 'slowed' down approval to wait for Eden.
Which is what you were implying they said..js
Followers
|
1616
|
Posters
|
|
Posts (Today)
|
17
|
Posts (Total)
|
685405
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |